```html

Xerostomic Mucositis – A Complete Medical Guide

Overview

Xerostomic mucositis is a form of oral mucosal inflammation that occurs in the setting of reduced salivary flow (xerostomia). It is most commonly seen in patients undergoing intensive cancer therapies—especially radiation to the head and neck or high‑dose chemotherapy—but can also arise from autoimmune disorders, medication side‑effects, or chronic salivary gland disease.

• Who it affects: Adults receiving head‑and‑neck radiation, hematopoietic stem‑cell transplant recipients, patients with Sjögren’s syndrome, and individuals taking anticholinergic or antihistamine medications.
• Prevalence: Up to 80 % of patients receiving curative radiation for head‑and‑neck cancers develop xerostomia, and of those, 40–60 % develop clinically evident mucositis (Mayo Clinic, 2023). In chemotherapy alone, mucositis occurs in 20–30 % of cycles, with xerostomia present in roughly half of those cases (ASCO, 2022).

Symptoms

Symptoms result from two overlapping processes—dry mouth and mucosal injury. The typical presentation includes:

• Dry, sticky sensation: The mouth feels parched even after drinking fluids.
• Redness and swelling of oral mucosa: Often begins at the junction of the soft palate and the tongue.
• Painful ulcerations: Small, shallow sores that can coalesce into larger lesions.
• Sores that bleed easily: Minor trauma (tooth brushing, eating) may cause bleeding.
• Altered taste (dysgeusia): Food may taste metallic or bland.
• Difficulty swallowing (dysphagia): Especially with solid foods.
• Speech changes: Slurred or halting speech due to discomfort.
• Burning or tingling sensation: Often described as “burning mouth syndrome.”
• Halitosis (bad breath): Bacterial overgrowth thrives in a dry environment.
• Increased dental decay: Reduced saliva diminishes its natural protective functions.

Causes and Risk Factors

Understanding the underlying cause helps tailor prevention and treatment.

Primary Causes

• Radiation therapy: Doses >30 Gy to salivary glands damage acinar cells, leading to permanent or temporary xerostomia.
• Chemotherapy: Cytotoxic agents (e.g., methotrexate, 5‑fluorouracil, cytarabine) target rapidly dividing mucosal cells, causing ulceration; concomitant drug‑induced salivary hypofunction worsens the picture.
• Hematopoietic stem‑cell transplantation (HSCT): Conditioning regimens combine high‑dose chemo and total‑body irradiation, raising risk to >70 %.
• Autoimmune diseases: Sjögren’s syndrome, systemic lupus erythematosus, and graft‑versus‑host disease can diminish saliva production.
• Medications: Anticholinergics, tricyclic antidepressants, antihistamines, and some antihypertensives reduce salivary output.
• Salivary gland disorders: Chronic sialadenitis, obstructive stones, or surgical removal of glands.

Risk Factors

• Age > 65 years (salivary flow naturally declines).
• Pre‑existing xerostomia or reduced baseline salivary flow.
• Concurrent smoking or alcohol use (irritates mucosa).
• Poor oral hygiene.
• High cumulative radiation dose or large treatment fields.
• Use of combination chemotherapy regimens.

Diagnosis

Diagnosis rests on clinical assessment supported by objective measures.

Step‑by‑step approach

1. History & Physical Exam: Inquiry about recent cancer therapy, medication list, and symptom timeline; visual inspection of oral cavity for erythema, ulceration, and dryness.
2. Salivary Flow Measurement:
   • Unstimulated whole‑saliva collection (spitting method) – < 0.1 mL/min indicates severe xerostomia.
   • Stimulated flow (using citric acid) – < 0.7 mL/min is abnormal.
3. Scoring Systems: WHO Oral Mucositis Grading Scale or the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (grade 1‑4).
4. Laboratory Tests (if infection suspected): CBC, cultures of ulcer exudate, or PCR for viral pathogens (HSV, CMV).
5. Imaging (rarely needed): MRI or ultrasound to evaluate salivary gland structural damage in chronic cases.

Treatment Options

Management combines symptom control, promotion of healing, and protection of the remaining salivary function.

Pharmacologic Measures

• Saliva Substitutes & Stimulators:
  • Over‑the‑counter artificial saliva gels (e.g., Biotène, Ora‑Gel).
  • Prescription sialogogues: Pilocarpine 5 mg PO qID or Cevimeline 30 mg PO BID (effective in radiation‑induced xerostomia)【1】.
• Topical Analgesics:
  • Benzydamine mouthwash (0.15 %); reduces pain and inflammation.
  • Lidocaine 2 % lozenges or viscous solution for breakthrough pain.
• Anti‑inflammatory/Antimicrobial Agents:
  • Triamcinolone acetonide dental paste for localized ulcer relief.
  • Chlorhexidine gluconate 0.12 % rinse (2 × daily) to control bacterial overgrowth; avoid prolonged use (>2 weeks) due to staining.
  • Systemic antifungals (e.g., fluconazole) if candidiasis develops.
• Growth‑factor Therapies (investigational): Palifermin (keratinocyte growth factor) has FDA approval for mucositis in HSCT; data show reduced severity when combined with radiation.

Procedural Interventions

• Low‑level laser therapy (LLLT): 630–660 nm light applied 2–3 times weekly shortens healing time (Cochrane Review 2022).
• Hyperbaric oxygen (HBO): Consider for radiation‑induced xerostomia refractory to medical therapy; 20–30 sessions may improve flow.
• Botulinum toxin injections: In selected cases of salivary gland hyperfunction causing discomfort; not commonly used for xerostomia.

Lifestyle & Supportive Care

• Frequent sips of water (preferably plain or slightly acidic to stimulate flow).
• Avoid alcohol‑based mouthwashes, tobacco, and spicy/acidic foods that exacerbate pain.
• Use a soft‑bristled toothbrush and fluoride‑containing toothpaste.
• Chew sugar‑free gum (xylitol) or suck on oral moisturizers every 2–3 hours.
• Maintain optimal nutritional intake—high‑protein, non‑acidic smoothies or soups.

Living with Xerostomic Mucositis

Daily management focuses on moisture maintenance, oral hygiene, and pain control.

• Hydration Schedule: Aim for 2–3 L of fluid per day; set alarms if needed.
• Oral Care Routine:
  1. Brush after each meal with a soft brush.
  2. Floss gently with floss picks or interdental brushes.
  3. Rinse with a neutral‑pH, alcohol‑free mouthwash (e.g., saline or bicarbonate solution).
• Moisturizing Products: Carry an oral moisturizing spray (e.g., Saliva Orthana) for on‑the‑go relief.
• Dietary Adjustments: Pureed or soft foods, avoid crunchy nuts, raw vegetables, and overly salty items.
• Regular Dental Visits: Every 3–4 months for professional cleaning and early detection of caries.
• Psychosocial Support: Join support groups for cancer survivors; anxiety and depression can worsen perception of oral pain.

Prevention

While some risk (e.g., cancer therapy) cannot be eliminated, several evidence‑based measures reduce incidence and severity.

• Pre‑treatment dental assessment: Treat existing caries and infections before radiation/chemotherapy begins (American Dental Association, 2023).
• Intensity‑modulated radiation therapy (IMRT): Sparing of salivary glands lowers xerostomia rates from 80 % to ~30 %.
• Amifostine prophylaxis: Intravenous amifostine (200 mg/m²) before radiation can reduce mucositis severity, though side‑effects (nausea) limit use.
• Oral hygiene education: Brush and floss regularly; use fluoride rinse.
• Saliva‑stimulating practices: Chew sugar‑free gum at least three times daily during treatment.
• Medication review: Discuss with the prescribing physician any drugs that exacerbate dry mouth; consider alternatives when possible.

Complications

If left untreated, xerostomic mucositis can lead to serious health problems.

• Secondary infections: Bacterial, fungal (candidiasis), or viral (HSV) infections of ulcerated tissue.
• Nutrition deficits: Painful eating → weight loss, dehydration, electrolyte imbalance.
• Odontogenic complications: Rapid dental decay, root caries, and periodontitis due to loss of protective saliva.
• Speech and swallowing impairment: May necessitate feeding tube placement.
• Quality‑of‑life deterioration: Chronic pain, social isolation, and depression.

When to Seek Emergency Care

---

Sources: Mayo Clinic. (2023). Radiation therapy side effects.; American Society of Clinical Oncology. (2022). Guidelines for mucositis management.; National Cancer Institute. (2024). CTCAE v5.0.; Cochrane Database of Systematic Reviews. (2022). Low‑level laser therapy for oral mucositis.; NIH. (2023). Pilocarpine for xerostomia..

```